Navigation Links
VWR Funding, Inc. Announces Proposed Offering Of Senior Notes
Date:8/20/2012

RADNOR, Pa., Aug. 20, 2012 /PRNewswire/ -- VWR Funding, Inc. (the "Company"), the parent company of VWR International, LLC, a leading global laboratory supply and distribution company, announced today that it intends to commence an offering of $750 million in aggregate principal amount of senior notes due 2017 (the "Notes"). The Notes will be senior unsecured obligations of the Company and will be guaranteed by certain of its domestic subsidiaries.

(Logo:  http://photos.prnewswire.com/prnh/20101109/NY97837LOGO )

The Company intends to use the net proceeds from the sale of the Notes to repurchase and/or redeem any and all of the approximately $713 million aggregate principal amount of its 10.25%/11.25% senior PIK toggle notes due 2015, pay the associated prepayment premium, fees and expenses incurred in connection with the repurchase and/or redemption of such notes and for general corporate purposes.

The Notes and related guarantees will be offered only to "qualified institutional buyers" in reliance on the exemption from registration pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act") and to persons outside of the United States in compliance with Regulation S under the Securities Act.  The Notes and the related guarantees will not be registered under the Securities Act, or the securities laws of any state or other jurisdiction, and, unless so registered, may not be offered or sold in the United States without registration or an applicable exemption from the Securities Act and applicable state securities and foreign securities laws. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act and does not constitute an offer to sell or a solicitation of an offer to buy any of the Notes, nor does it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. 

Forward Looking Statements

Any statements contained herein that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are generally identifiable by use of the words "believes," "expects," "intends," "anticipates," "plans to," "estimates," "projects," or similar expressions.  Such statements may include, but are not limited to, statements about the Company's business outlook and financial guidance and other statements that are not historical facts.  Such statements are based upon the beliefs and expectations of the Company's management as of this date only and are subject to certain risks and uncertainties that could cause the actual results to differ materially, including, without limitation, those items identified as "risk factors" in the Company's most recently filed Form 10-K and Form 10-Q.  Therefore, readers are cautioned not to place undue reliance on these forward-looking statements.  The Company undertakes no obligation to revise or publicly release the results of any revision to these forward-looking statements other than through its various filings with the Securities and Exchange Commission.


'/>"/>
SOURCE VWR
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. VWR Funding, Inc. Announces Tender Offer Of Existing PIK Toggle Notes
2. Bausch + Lomb Announces Final Results for Its Previously Announced Tender Offer for Its 9 7/8% Senior Notes due 2015 (CUSIP Nos. 071707AN3, U07190AA6 and 071707AP8)
3. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
4. ShangPharma Announces Second Quarter 2012 Results
5. Nectid Announces Initiation Of Clinical Development Of Autism And Pain Drugs
6. Apexigen Announces the Filing of an IND by its Partner, 3SBio
7. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
8. Perrigo Company Announces Quarterly Dividend
9. Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
10. Cambrex Announces Significant New Supply Agreement
11. Sunpeaks Ventures Announces Second Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016 Eurofins ... accreditation from the College of American Pathologists (CAP) ... (CLIA) for its new laboratory in ... moved its North American headquarters. "Our ... sequencing -- which is still considered the ,Gold ...
(Date:12/6/2016)... -- With opioids commonly used for pain management for workplace injuries, ... has led to nationwide fatalities. The synthetic opioid called ... heroin or morphine, resulting in likelihood of addiction, abuse or death. ... , , ... Behavioral Health for HMC HealthWorks, explained the opioid drug is less ...
(Date:12/6/2016)... new study released today by the Alliance for ... Drug Pricing Program will continue to expand at an unprecedented ... exceed $23 billion in total purchases at the 340B price. ... Part B drug reimbursement purchases over the next five years. ... of data on total drug purchases through 340B from 2005 ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... , ... “Tomorrow Trump Goes To Washington”: a brief but engaging illustration ... to America. “Tomorrow Trump Goes To Washington” is the creation of published author, Nancy ... country. , Nancy attributes her patriotic nature to her WWII veteran father. She ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... Angioma Alliance ... cerebral cavernous angiomas, was awarded a grant from the Julian Grace Foundation to ... Mexico has more people with cavernous angioma than anywhere in the world. Most ...
(Date:12/7/2016)... ... , ... NuevaCare, a leading home care agency based in San Mateo but ... as part of its ambitious website relaunch. As Bay Area clients scramble to find ... serving their city. The new site has several key city-specific pages to address this ...
(Date:12/6/2016)... ... 06, 2016 , ... The International Vaccine Institute (IVI) and ... the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The collaboration will accelerate MERS-CoV vaccine ... deployment in the event of a future outbreak. , IVI and GeneOne held ...
(Date:12/6/2016)... ... December 06, 2016 , ... According to a November ... such as consuming too many mints or not drinking enough water, which can cause ... California Dental Care notes that good oral hygiene not only helps reduce the possibility ...
Breaking Medicine News(10 mins):